|Description||The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL receptor. It seems to be more common in non-small cell lung cancer and it is still under Phase I|
|Synonyms||MGCD265 hydrochloride; MGCD-265 hydrochloride; MGCD 265 hydrochloride|
|Solubility||DMSO: ≥ 28 mg/mL|
|Application||The hydrochloride salt form of Glesatinib could be effectively targeting tumors that are driving to grow through MET and AXL receptor.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Mirati Therapeutics|
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron a...
MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
This active molecular is a selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been reported that it usually overexpressed in...
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
Lys01 trihydrochloride, a water-soluble salt of Lys01, is a selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respec...
LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K(i)) of 2 nM, a pharmacodynamic residence time ...
PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor and is susceptible to oncogenic mutations (no activity to Y1230C mutant). It showed ...
AMG 337 is an orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-M...
MK-8033 binds 3-fold more tightly to phosphorylated c-Met kinase domain (Kd= 3.2 nM) than to its unphosphorylated counterpart (Kd = 10.4 nM). Signigicantly, MK-...
PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral adminis...
NVP-BVU972 potently inhibits MET kinase but displays low inhibition against other kinases including the most closely related kinase RON with IC50 values of more...
golvatinib (also known as E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial ...
The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL r...
Potent inhibitor of MET, VEGFR2, Ron and AXL (IC50 values are 0.4, 0.9, 3 and 11 nM, respectively). Also potently inhibits Tie-2, Flt-1, Flt-3, Flt-4, KIT, PDGF...
Capmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with...
PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling c-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL....
Savolitinib is a tyrosine kinase inhibitor with potential anticancer activity.
Tivantinib (ARQ-197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-...
SU11274 is a selective Met tyrosine kinase inhibitor with IC50 of 10 nM.
MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met. MK-2461 inhibited in vitro phosphorylation of a peptide substrate recognized by w...